Overcoming therapeutic resistance in driver-negative NSCLC: Immunomodulatory mechanisms and clinical efficacy of Camrelizumab-chemotherapy combination in a real-world cohort

Abstract Background Driver gene-negative advanced non-squamous non-small cell lung cancer (NSCLC) exhibits inherent resistance to conventional therapies, representing a significant treatment challenge. The limited efficacy of platinum-based chemotherapy alone underscores the need for resistance-miti...

全面介紹

書目詳細資料

發表在:	Discover Oncology
Main Authors:	Yan Ge, Yang Zhao
格式:	Article
語言:	英语
出版:	Springer 2025-06-01
主題:	NSCLC Camrelizumab Treatment resistance Immunomodulation PD-1 Inhibition Chemoimmunotherapy
在線閱讀:	https://doi.org/10.1007/s12672-025-02926-0